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Abstract
PTTG Binding Factor (PBF or PTTG1IP) is a little characterised proto-oncogene that has been
implicated in the etiology of breast and thyroid tumors. In this study, we created a murine
transgenic model to target PBF expression to the thyroid gland (PBF-Tg mice) and found that
these mice exhibited normal thyroid function but a striking enlargement of the thyroid gland
associated with hyperplastic and macrofollicular lesions. Expression of the sodium iodide
symporter (NIS), a gene essential to the radioiodine ablation of thyroid hyperplasia, neoplasia and
metastasis, was also potently inhibited in PBF-Tg mice. Critically, iodide uptake was repressed in
primary thyroid cultures from PBF-Tg mice, which could be rescued by PBF depletion. PBF-Tg
thyroids exhibited upregulation of Akt and the TSH receptor (TSHR), each known regulators of
thyrocyte proliferation, along with upregulation of the downstream proliferative marker cyclin D1.
We extended and confirmed findings from the mouse model by examining PBF expression in
human multinodular goitres (MNG), a hyperproliferative thyroid disorder, where PBF and TSHR
was strongly upregulated relative to normal thyroid tissue. Further, we showed that depleting PBF
in human primary thyrocytes was sufficient to increase radioiodine uptake. Together, our findings
indicate that overexpression of PBF causes thyroid cell proliferation, macrofollicular lesions and
hyperplasia, as well as repression of the critical therapeutic route for radioiodide uptake.
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Precis This study of a little characterized proto-oncogene in thyroid hyperplasia and neoplasia reveals that it functions in blocking the
chief route of radioiodine uptake which is vital for clinical treatment of thyroid cancer.
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Introduction
Described in only eleven publications (1-11) Pituitary Tumor Transforming Gene binding
factor (PBF) was identified through its ability to interact with PTTG1, the human securin
(3). PBF comprises 6 exons spanning 24 Kb within chromosomal region 21q22.3. The 180
amino acid peptide sequence of PBF shares no significant homology with other human
proteins, but is highly conserved across a wide diversity of animal species (73% homology
to mouse, 67% frog, 60% chicken, 52% zebra fish), suggesting both unique function and
significant evolutionary importance. PBF is widely expressed in normal human tissues,
including normal thyroid (3, 10). Whilst expression is low in normal breast tissue,
immunohistochemical analysis demonstrated that PBF was strongly expressed in epithelial
cells of all types and grades of breast tumour assessed (11).
Initial protein prediction studies suggested that PBF was a cell surface glycoprotein due to a
potential N-terminal signal peptide, transmembrane domain, endocytosis motif and two
putative N-glycosylation sites (10). PBF also possesses an extracellular N-terminal cysteine-
rich region, similar to that found in the membrane-associated plexins, semaphorins and
integrins (12). In contrast to evidence supporting the characterisation of PBF as a membrane
protein, the presence of a bipartite nuclear localisation signal (NLS) near the C-terminus
suggested PBF may also be a nuclear protein (3).
We previously characterised PBF expression in thyroid cancers, and demonstrated it to be a
transforming gene in vitro, and to be tumourigenic in vivo (8). Furthermore, high PBF
expression was independently associated with poor prognosis in human differentiated
thyroid cancer. Most recently, we showed that PBF represses iodide uptake in thyroid cells
in vitro, both through transcriptional regulation (2) and altered subcellular trafficking (6) of
the sodium iodide symporter (NIS). Outside the thyroid, we recently described a role for
PBF in the aetiology of breast cancer (11), and defined PBF function in a mouse model of
Downs’ Syndrome angiogenesis (5).
PBF is thus a relatively uncharacterised protein implicated in multiple cellular processes,
particularly in the setting of endocrine neoplasia. However, the precise function of PBF in
vivo, and the oncogenic potential of PBF within a specific organ, has not been tested. Whilst
subcutaneous injection of stable NIH3T3 lines over-expressing PBF elicited large and
aggressive tumours in nude mice (8), a more physiological appraisal of tumour induction is
lacking. Thus, to investigate the function of PBF in vivo, we generated a murine transgenic
model of PBF expression (PBF-Tg) targeted to the thyroid gland. We now present extensive
data suggesting that PBF regulates thyroid gland growth through increased cell proliferation,
an effect that is independent of thyroid function and growth factor induction, and induces
significant hyperplasia. Furthermore, we propose that PBF represents a gene of direct
clinical relevance to thyroid hyperplasia and neoplasia, given that it is over-expressed in
human MNG and potently represses iodide uptake in vivo.
Methods
Generation of PBF-Tg transgenic mice
WT and transgenic PBF-Tg mice were bred at the University of Birmingham and all
experiments performed in accordance with U.K. Home Office regulations. The generation of
the PBF-Tg transgenic line was performed by microinjection of fertilized mouse oocytes
with the Tg-PBF-HA transgene and subsequent transfer into pseudopregnant females, as per
standard protocols (13-14). Further details on construction of the Tg-PBF-HA transgene are
provided in Supplementary Fig. S1.
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Transgene copy number was determined by real-time RT-PCR essentially as described
previously (15). Primers used to detect the human PBF gene were 5′-
GCTTGTCTGGACTACCCAGTTACA-3′ (forward), 5′-
AGCGTGCAGAGCTCAATTTACA-3′ (reverse) and 5′
FAMCGTCTTGCCACCGGCTTCCCT-3′ (probe). To normalise DNA in PCR reactions
we used primers 5′-CAGAAAACCATGAGAGGCAATG-3′ (forward), 5′-
TTCTCCCATGAGACGACAGTGA-3′ (reverse) and 5′
VICTTCAAGTGCATTATCCCCTCCTCGGTG-3′ (probe) directed to a 89 bp sequence in
the DSCAM gene, which is conserved between mouse and human genomes.
RNA extraction, reverse transcription quantitative PCR and Western blot analysis
Total RNA was extracted from mouse thyroids using the RNeasy Micro Kit (Qiagen) and
reverse transcribed using the Reverse Transcription System (Promega), as previously
described (2). Expression of specific mRNAs was determined using 7500 Real-time PCR
system (Applied Biosystems; ref (16)). Western blot analysis was performed as we have
described previously (1, 6, 17). After blocking Western gels were probed with specific
antibodies against TSHR (H-155), (Santa Cruz Biotechnology), 1:500; TSHR (2C11), (AbD
Serotec), 1:200; phospho-Akt (Ser473) (D9E) XP (Cell Signalling Technology), 1:1000;
total Akt, (Millipore), 1:1000 and PBF (6, 11), 1:1000.
Immunohistochemistry
Mouse thyroid specimens were immunostained with specific antibodies against cyclin D1,
(Abcam), 1:100; HA, (Covance Research Products), 1:1000 and NIS, (Alpha Diagnostic
Intl), 1:50 using protocols as described previously (8, 18). Immunostained sections were
counterstained with Mayer’s hematoxylin. For negative controls the primary antibody was
replaced by 10% normal goat serum.
Analysis of thyroid morphology
Thyroid glands were removed from mice aged between 4 and 78 weeks using a dissecting
microscope. H&E and immunostained thyroid tissue sections were viewed under a light-
microscope (Zeiss) and images captured using Axiovision software (Version 4). The
diameter of thyroid follicles (major axis) was measured using ImageJ software. A standard
100 μm scale bar (Axiovision) was used to convert pixels to μm.
Primary thyrocyte culture, siRNA transfection and iodide uptake assays
Primary thyrocyte cultures were performed as described previously (17, 19). Seven days
after seeding thyrocyte cultures were transfected with PBF-specific and control siRNA
(Ambion) by lipofectamine-2000 (Invitrogen) using standard protocols. 72 hours post-
transfection, iodide (125I) uptake assays were performed to assess NIS function as described
previously (6). Relative iodide uptake was corrected for protein concentration as measured
by the Bradford assay.
Thyroid function tests
Total T4 and total T3 in serum of WT and PBF-Tg mice were measured after centrifugation
of clotted blood samples using RIA kits (MP Biomedicals). Mouse serum TSH
concentrations were determined by the laboratory of Prof Samuel Refetoff (University of
Chicago, USA). Details of this assay have been published (20).
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Human thyroid samples
Collection of thyroid samples was in accordance with approval of the Local Research Ethics
committee, and subjects gave informed written consent. Normal thyroid was obtained from
the contralateral lobe at the time of surgery.
Statistics
Data are displayed as mean ± SEM. All statistical tests were performed with the 2-tailed
Student’s t-test, unless otherwise indicated. P values < 0.05 were considered significant.
Results
A murine model of thyroid-targeted PBF induction
To investigate the physiological effect of enhanced PBF expression within thyroid follicular
epithelial cells, we constructed a FVB/N transgenic line with targeted expression of PBF
driven by the bovine thyroglobulin promoter (Fig. 1A). Real-time PCR-based zygosity
assays indicated that a single copy of the Tg-PBF-HA transgene had integrated into the
genomic DNA of the founder mouse and in G1 hemizygotes (Supplementary Fig. S2).
Quantification of PBF transgene expression in PBF-Tg thyroids showed an ~7-fold increase
relative to endogenous PBF protein levels in wild-type (WT) thyroids (Fig. 1B). There was
no significant expression of the PBF transgene in other major organs examined, including
the liver, kidney and spleen (Supplementary Fig. S3). Immunohistochemistry using an anti-
HA antibody revealed intense brown staining of the HA-tagged transgene in thyroid
follicular epithelial cells, where it was predominantly localised within the cytoplasm (Fig.
1C).
Male PBF-Tg mice showed no significant change in body weight compared with WT litter-
mates up to 10 weeks (Fig. 1D). In contrast, there was a slight increase in body weight of
female PBF-Tg mice at both 7 (13.4% weight gain, P < 0.0001) and 10 (5.5% weight gain, P
= 0.04) weeks of age compared to female WT mice. Survival was non-significantly
decreased in PBF-Tg mice (Fig. 1E, 14 ± 5 % decrease compared with WT by 18 months of
age, P = 0.127). No consistent cause of death was identified in those PBF-Tg mice which
died earlier than WT.
PBF-Tg mice show enlarged thyroid glands and altered follicular structure
The most striking phenotype of PBF-Tg mice was an increase in thyroid size and weight.
PBF-Tg thyroid glands were 1.7-fold heavier than those of WT litter-mates by 6-7 weeks,
and up to 3.2 times heavier by 52 weeks (Fig. 2A and Supplementary Fig. S4). At 52 weeks
of age, the mean thyroid weight of PBF-Tg mice was 10.0 ± 0.6 mg compared with 3.26 ±
0.13 mg for WT mice. Increased thyroid size persisted to 78 weeks (Fig. 2A). Interestingly,
thyroid glands from female PBF-Tg mice were significantly larger than those of male PBF-
Tg littermates at 52 weeks of age (38.5% weight difference, P = 0.0045, Supplementary Fig.
S4C). Critically, the penetrance of increased thyroid weight in PBF-Tg mice was 100%,
with all transgenic mice demonstrating markedly enlarged thyroid glands (n = 213). In
addition, the thyroid glands of transgenic mice had a superficially nodular appearance on
macroscopic evaluation (Fig. 2B).
To examine mouse thyroid glands microscopically, we performed H&E staining on sections
from PBF-Tg and WT mice. Composite images of complete thyroid lobes from PBF-Tg and
WT mice demonstrated that the increased size of PBF-Tg thyroids (3-4 mm compared with
2 mm overall length, respectively, Fig. 2C) might be due to an increased follicular diameter
(Fig. 2D). To quantify this structural difference, we measured the diameter of >3000
follicles in PBF-Tg and WT mice at 26 weeks of age (N = 5 PBF-Tg and 7 WT mice; Fig.
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2E). WT mice had an increased frequency of smaller diameter follicles of <50 μm diameter
(P < 0.0001 compared with PBF-Tg). In contrast, transgenic mice showed a greater
preponderance of follicles which exceeded 50 μm diameter than WT (50-100 μm, P =
0.0027; 100-150 μm, P < 0.0001; 150-200 μm, P = 0.0042, N = 12, PBF-Tg v WT in each
case). The mean follicle diameter in PBF-Tg mice (81.3 ± 0.2 μm, N = 1444) was also
greater compared with WT mice (59.1 ± 0.1 μm, N = 1759, P = 0.0002). Thus, thyroids of
PBF-Tg mice at 26 weeks of age are larger and heavier than matched WT litter-mates at
least partially due to an increased frequency of large diameter follicles.
Thyroid-specific over-expression of PBF induces hyperplastic lesions
PBF has previously been shown to induce subcutaneous tumours in nude mice (8).We
therefore examined thyroid morphology at 26, 52 and 78 weeks of age (Fig. 3 and
Supplementary Fig. S5 and 6). PBF-Tg mice were prone to macrofollicular lesions, with
>65% mice demonstrating macrofollicular lesions by 52 weeks of age, and >90% by 78
weeks (P = 0.0217 compared with WT, Fig. 3A and C and Supplementary Fig. S5).
Macrofollicular lesions were also occasionally present in aging WT mice, but with lower
frequency (Fig. 3A). Focal and nodular hyperplasia was also prominent, with 75% of PBF-
Tg mice demonstrating evidence of hyperplastic lesions by 78 weeks of age (Fig. 3B, P =
0.009 compared with WT mice). Representative images of thyroid hyperplasia in 52 and 78
week old PBF-Tg mice are highlighted (Fig. 3D and F-I and Supplementary Fig. S6). Close
examination of hyperplastic lesions also revealed the presence of larger nuclei (arrowed), a
finding which is consistent with proliferating cells (Fig. 3H). In contrast, there were no
hyperplastic lesions present in WT mice thyroids at any age (Fig. 3B and E). Whilst
hyperplasia was prevalent in PBF-Tg mice there was no tumour induction, suggesting that
although over-expression of PBF within murine thyroid follicular epithelial cells induces
gross morphological changes and hyperplasia, it is insufficient alone to elicit cell
transformation.
Thyroid function and gene expression responses to targeted PBF expression
We next investigated thyroid function in response to transgene expression in 6-7 week old
PBF-Tg and WT mice by determining serum levels of total triiodothyronine (T3), thyroxine
(T4) and TSH. Serum TSH levels were not elevated in either male or female PBF-Tg mice
compared to sex-matched WT mice (Fig. 4A, N = 6 in each group). In addition, there was no
significant difference between serum TSH levels in 12 month old PBF-Tg and WT mice
(data not shown). In keeping with this, total T3 and T4 serum concentrations in PBF-Tg
mice were not markedly altered compared with WT mice (Supplementary Fig. S7). These
results indicate that PBF over-expression in the thyroid gland does not significantly alter
thyroid function, resulting in increased serum TSH levels and hence stimulated thyroid cell
growth.
To probe the mechanisms of induction of thyroid growth we next investigated growth factor
and TSH receptor (TSHR) expression in PBF-Tg mice. Expression of mRNAs encoding
VEGF, TGFβ, EGF and IGF-1 was unaltered in PBF-Tg versus WT mice (Fig. 4B). Given
that PBF has previously been implicated in the stimulation of FGF-2 expression by its
binding partner PTTG, an unexpected finding was that FGF-2 showed a mild 25% reduction
in expression in PBF-Tg mice (P = 0.005). In contrast, TSHR mRNA expression was
significantly enhanced in PBF-Tg mice (2.0 ± 0.2-fold, P = 0.0002). Additionally, TSHR
mRNA was increased by 2.3±0.4-fold in primary thyrocyte cultures from PBF-Tg mice after
14-days of culture compared with WT (P = 0.02, N = 8; Fig. 4C). We next examined TSHR
protein expression (Fig. 4D). Scanning densitometry confirmed that TSHR expression
overall was significantly induced in PBF-Tg thyroids compared with matched WT mice (2.6
± 0.4-fold, P = 0.021).
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Given that TSHR showed dysregulation, we next examined the mRNA expression of 4
further critical thyroid genes (Fig. 4E). Whilst PTTG has previously been shown to stimulate
PBF expression in vitro (8), there was no reciprocal relationship in vivo, with PTTG mRNA
expression unaffected by PBF over-expression (Fig. 4E). Thyroglobulin (Tg), thyroid
transcription factor 1 (TTF1) and paired box gene 8 (PAX8) expression were also similar in
PBF-Tg and WT mice. However, mRNA expression of the sodium iodide symporter NIS
was repressed by ~50% in age and sex-matched PBF-Tg mice compared with WT (Fig. 4E,
P = 0.0004). Assessment of NIS immunostaining in thyroid sections revealed a
heterogeneity of NIS expression across whole thyroid lobes (Supplementary Fig. S8), but
with an overall reduction in NIS protein expression in PBF-Tg mice compared to WT (Fig.
4F).
PBF represses sodium iodide symporter function in vivo
We have previously reported that PBF inhibits iodide uptake in vitro (2, 6). Given that PBF-
Tg mice showed repressed NIS mRNA and protein expression, we examined NIS function
in our transgenic mouse model. We thus performed primary cultures of thyroid cells from
age and sex-matched PBF-Tg and WT mice, and performed 125I uptake assays after 7 days
of culture (Fig. 4G). Uptake was in the range of 3,000 to 13,000 cpm/μg protein. Results
corrected for protein concentration revealed a potent and significant ~70% repression of 125I
uptake in PBF-Tg mice compared with WT (P = 0.0004).
To determine whether the repression of radioiodide uptake – a critical issue in the treatment
of benign and malignant thyroid disease – could be ameliorated, we transfected primary
thyrocyte cultures from PBF-Tg mice with siRNA targeted to PBF. Following successful
PBF knockdown (Fig. 4H), 125I uptake increased 2.4 ± 0.64-fold (Fig. 4I) to levels
indistinguishable from WT (P = 0.86), whereas transfection using a scrambled siRNA did
not alter 125I uptake. Thus, our findings validate our previous in vitro reports that PBF
represses NIS, demonstrating potent inhibition of NIS expression and function in thyroid
cells in vivo. Furthermore, the repressed iodide uptake phenotype of PBF transgenic mice
could be rescued by transiently down-regulating PBF expression.
PBF over-expression induces thyroid cell proliferation in vivo
Because thyroid cell growth is regulated by a series of well described kinase pathways
which are frequently disrupted in neoplasia, we next investigated expression of proteins
involved in the mitogen activated protein kinase (MAPK) and phosphoinositide 3-kinase
(PI3K) pathway to understand how PBF might induce thyroid growth. Whilst MAPK was
not altered in PBF-Tg mice compared with WT (Supplementary Fig. S9), phosphorylation of
the PI3K target AKT (pAkt) was significantly induced by 3.2 ± 0.33-fold (Fig. 5A, N = 7, P
= 0.00014). In contrast, cellular expression of total Akt was unchanged (0.87 ± 0.08-fold, N
= 8, P = 0.39) in PBF-Tg mice. In support of this, Figure 5B shows that transient PBF over-
expression in human thyrocytes similarly resulted in clear and significant activation of pAkt
24 hours post-transfection, whilst there was no difference in total AKT in human thyrocytes
transfected with either vector only or pcDNA3-PBF.
We next assessed whether elevated pAkt might induce a downstream proliferative change by
determining expression of the proliferative marker cyclin D1 in > 60,000 follicular epithelial
cells from PBF-Tg and WT mice. Positive immunostaining with cyclin D1 was 2.7- to 3.4-
fold greater in diffuse goitre regions of PBF-Tg mice by 52 (P < 0.0001) and 78 (P =
0.00016) weeks of age respectively compared to WT mice (Fig. 5C and D and
Supplementary Fig. S10A). Taking the data as a whole, the mean percentage of cyclin D1
positive follicular epithelial cells in aged PBF-Tg mouse thyroid glands was 13.4% (N =
4834/35958 cells, P < 0.0001) compared with 4.7% in WT mice (N = 1231/25987 cells).
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Further, hyperplastic regions of aged PBF-Tg mice demonstrated much greater cyclin D1
staining in follicular epithelial cells, ranging from 19% to 68%, with a mean value of 37.7 ±
20.7% (Fig. 5E and Supplementary Fig. S10B-D). Altogether, these results show that PBF
over-expression results in increased thyroid cell proliferation in vivo, which is associated
with activation of the Akt signalling pathway, as well as increased TSHR.
PBF and NIS expression and function in human MNG
PBF has previously been shown to be increased in differentiated thyroid cancer (8), but has
not been examined in thyroid hyperplasia. Given that PBF induced goitre formation in our
murine model, we next assessed PBF mRNA and protein expression in human MNG (Fig.
6). PBF mRNA was increased 2.2 ± 0.3-fold, with scatter plot analysis showing that PBF
mRNA expression was up to 5.6-fold higher in MNG than in normal thyroid (Fig. 6A).
Protein expression was similarly induced in MNG compared with normal thyroid (2.3 ± 0.3-
fold, P = 0.018; Fig. 6B). We further assessed TSHR upregulation in MNG tissue samples.
In direct support of our in vitro and in vivo data, human MNG tissue samples demonstrated
a 4.5 ± 0.7-fold increase in TSHR protein expression compared to normal tissue (P = 0.003;
Fig. 6B).
In contrast to PBF and TSHR, NIS mRNA expression was significantly reduced in MNG
(38% reduction, P = 0.002) compared with normal thyroid (Fig. 6C). Since we have shown
in the PBF-Tg mouse that PBF reduces NIS expression, potential associations between these
two genes in human MNG were examined. A significant negative correlation between PBF
and NIS mRNA expression was apparent in MNG specimens (Fig. 6D, rs = 0.39, P = 0.05).
Finally, to investigate whether over-expression of PBF in human thyroid hyperplasia and
neoplasia might represent a therapeutic target, we performed primary culture of normal
human thyrocytes, and investigated the outcome of manipulating PBF expression on
radioiodide uptake. As in murine cultures, siRNA treatment resulted in repressed PBF
expression in human thyrocytes (Fig. 6E), which was associated with a significant increase
in NIS mRNA expression by 2.1 ± 0.35-fold (P = 0.02) at 72 hours post-transfection (Fig.
6F). By contrast, there was no significant change in TSHR mRNA expression coincident
with NIS upregulation (Supplementary Fig. S11). Crucially, however, in comparison to
using scrambled siRNA, targeted repression of endogenous PBF expression in human
thyrocytes was associated with a significant gain in radioiodide uptake by 2.0 ± 0.14-fold
(Fig. 6G, P = 0.0001).
Discussion
The mechanisms governing thyroid cell growth in hyperplasia and neoplasia remain to be
fully defined, despite recent progress with well characterised oncogenes such as BRAF (21,
22). Our current study indicates that the relatively uncharacterised gene PBF should be
considered a new aetiological factor in the thyroid, as well as a novel therapeutic target.
A possible role for PBF in tumourigenesis was highlighted by previous data showing that
subcutaneous expression of murine fibroblasts over-expressing PBF induced high-grade
malignant tumour formation in athymic nude mice (8). To gain insights into the wider role
of PBF in thyroid disease, we constructed a PBF-Tg transgenic mouse model using the
bovine thyroglobulin promoter to mediate thyroid-specific PBF over-expression. In contrast
to our previous subcutaneous study, thyroid tumour induction was absent in this transgenic
mouse model. Instead, transgenic mice demonstrated thyroid enlargement with 100%
penetrance, with a high occurrence of both macrofollicular and hyperplastic thyroid lesions.
Our findings are paralleled by observations from the PtenL/L;TPO-Cre mouse model, in
which there is constitutive activation of the PI3K/Akt pathway in thyrocytes, extremely
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enlarged follicles and normal serum TSH concentrations (23). Hyperplasia and adenomas
also developed in the PtenL/L;TPO-Cre mouse by 10 months of age, which was associated
with an increase in thyrocyte proliferation (23). Thus, in concert with the PtenL/L;TPO-Cre
mouse model, PBF-Tg mice demonstrate molecular hallmarks of altered cell number and
morphology, evidenced by pAkt activation and increased cyclin D1 staining, but not
tumours. It is likely therefore that cooperation between PBF-induced Akt signalling and
mutations in other signalling cascades might be required to promote thyroid cancer
pathogenesis. The precedent for this lies again with the PtenL/L;TPO-Cre mouse, which
when crossed with mice harbouring a Kras oncogenic mutation led to invasive and
metastatic follicular carcinomas (24), whereas neither the Pten L/L;TPO-Cre or KrasG12D
mouse model alone developed thyroid carcinomas.
PBF protein in our transgenic thyroids was induced 7-fold compared to endogenous mouse
PBF expression, which was comparable to the highest fold increase in PBF expression in our
MNG samples. Hence, the striking enlargement of PBF-Tg mouse thyroids was most likely
the result of specific biological effects of PBF and not due to excessive exogenous protein
expression. Primarily, the growth of thyroid cells is induced by TSH, which is in turn
regulated by thyroid hormones through negative feedback at the anterior pituitary.
Surprisingly, thyroid growth in the PBF-Tg mouse was not stimulated by elevated serum
TSH levels. These results are in sharp contrast to the BRAFV600E mouse which had similar
enlargement of the thyroid gland but was associated with an 80-fold increase in TSH levels
in 5-week old mice (22). Instead, gross enlargement of the PBF-Tg mouse thyroid was
associated with increased TSHR expression and Akt activation. The precise mechanism by
which PBF induces TSHR and Akt is the subject of further work, and it would be interesting
in future long-term studies to place PBF-Tg mice on a thyroxine-supplemented diet to
suppress TSH, thereby investigating the extent to which goitrogenesis is mediated via the
TSH-TSHR axis.
Most activities of the TSHR are mediated through the Gαs protein, which activates the
adenylyl cyclase/cAMP cascade (25). Recent studies have also shown that TSH can
stimulate Akt phosphorylation in rat FRTL5 (26) and PCCL3 cells (27, 28), presumably
through coupling to Gβγ dimers and subsequent PI3K activation (28). These observations
would suggest that PBF induction of TSHR might directly confer activation of PI3K/Akt
signalling to promote thyroid cell proliferation in vivo. However, TSH effects on Akt
phosphorylation have so far only been demonstrated in vitro (26-28) and so further
investigations are required. It is possible that PBF over-expression might also activate Akt
signalling independently of TSHR. Indeed, we recently observed that PBF over-expression
can activate Akt in human colorectal HCT116 cells (unpublished observations).
The mechanism of PBF upregulation in human MNG is unknown. However, nodular thyroid
disease is markedly more common in females than males (29), and we recently
demonstrated in a separate study that PBF is oestrogen-regulated (11). PBF expression in
transgenic PBF-Tg mice was under the control of the thyroglobulin promoter, and hence
relatively immune to the effects of oestrogen. We did however observe significantly larger
thyroid glands in female PBF-Tg mice compared to male littermates at 52 weeks of age,
which might imply that oestrogen has a role in controlling PBF’s ability to induce thyroid
growth. Recently it was shown that circulating oestrogen can regulate thyroid cell
proliferation in PtenL/L;TPO-Cre mice, but not in WT mice (30). These findings raise the
possibility that PBF over-expression to activate PI3K/Akt signalling might be a contributory
factor in increasing the susceptibility of females to thyroid disease. It would therefore be
interesting to compare oestrogen status and PBF expression in a large series of human
MNG, as well as male versus female PBF expression in thyroid disease in general.
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Radioiodine is central to the treatment of thyroid cancer and toxic nodular hyperthyroidism.
It is also increasingly used as first line therapy in Graves’ disease (31) and to induce
shrinkage of benign goitres (32). Our murine data provide an important validation of our
earlier in vitro observations that PBF is a critical regulator of both NIS expression and
function (2, 6). Mice with targeted over-expression of PBF demonstrated a 70% repression
of iodide uptake in primary thyroid cultures. As we observed a ~50% inhibition of NIS
mRNA expression in PBF-Tg thyroids compared to WT controls, repressed iodide uptake in
PBF-Tg mice cultures may also reflect altered subcellular localisation of NIS (6). Whilst
two recent studies have implicated PI3K/Akt signalling in NIS inhibition (28, 33), the exact
mechanism for PBF-induced NIS mRNA repression remains to be fully clarified.
In MNG, NIS expression is heterogeneous, but is generally increased in hyperfunctioning
goitres and low in those that are non-toxic (34-37). Our data of reduced NIS expression in
MNG are therefore in keeping with those in the literature. Indeed, the observed phenotype is
similar to that of cold thyroid nodules that have reduced NIS mRNA levels and show
reduced iodide uptake on scintiscan (35). Importantly, we were able to demonstrate a
significant correlation between PBF and NIS mRNA expression in MNG, which further
emphasises the functional interaction between these two genes in vivo. In addition, we were
able to demonstrate that NIS expression was heterogeneous throughout the thyroid lobes of
PBF-Tg mice, mirroring the typical non-uniformity of radioiodine uptake in human MNG. It
will be important to investigate in future studies whether specific regions of high PBF
expression in human MNG represent thyroidal regions of lowered radioiodine uptake.
Of central importance to the current investigation is the observation that we were able to
rescue NIS repression by siRNA targeting of PBF both in primary thyroid cultures from
transgenic mice and in normal human thyrocytes. The functional interaction between PBF
and NIS was further demonstrated by a significant 2-fold increase in NIS mRNA expression
following siRNA targeting of PBF in primary human thyrocytes. These results therefore
suggest that PBF represents a promising and novel therapeutic target to overcome
radioiodine resistance in thyroid tumours and their metastases, as well as in thyroid disease
more generally.
In summary, we present evidence that the relatively uncharacterised proto-oncogene PBF
has specific relevance to thyroid cell growth. As well as inducing thyroid cell proliferation
and hence goitre in vivo, PBF represses the central therapeutic avenue for thyroid
hyperplasia and neoplasia. Thus, in addition to its established role in thyroid cancer, PBF
now needs to be further appraised as a critical gene in the aetiology and treatment of thyroid
disease as a whole.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Generation and characterisation of the PBF-Tg mouse model. A, Schematic of the bovine
thyroglobulin (Tg)-PBF-HA transgene. B, Detection of transgenic PBF (human) and
endogenous PBF (mouse) expression by Western blot analysis of PBF-Tg and WT thyroids.
C, Detection of HA-tagged PBF (brown staining) by immunohistochemistry in PBF-Tg and
WT thyroid sections. Scale bars: 50 μm. D, Body weight of male (M) and female (F) PBF-
Tg and WT mice at 4, 7 and 10 weeks of age (N = 7-45). Data presented as mean ± SE. E,
Kaplan-Meier survival curves for PBF-Tg (N = 82) and WT (N = 31) mice; P = 0.127.
Read et al. Page 12
Cancer Res. Author manuscript; available in PMC 2012 April 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Figure 2.
Enlarged thyroid glands in PBF-Tg mice. A, Thyroid weight of PBF-Tg and WT mice. ***P
< 0.0001 compared to age-matched WT mice. Mice numbers analysed are shown. B,
Representative images of thyroid glands from 52-week old PBF-Tg and WT mice. Dotted
line indicates margin of thyroid lobes. C, Representative images of H&E stained thyroid
sections from PBF-Tg and WT mice at 26 and 52 weeks of age. D, Higher magnification of
H&E stained sections of PBF-Tg and WT thyroids from 26 week old mice. Scale bars: 100
μm. E, Quantification of follicle diameter in PBF-Tg and WT thyroids from 26 week old
mice expressed as frequency per 100 follicles measured. Data presented as mean ± SE.
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Figure 3.
Thyroid hyperplasia in PBF-Tg mice. Occurrence of macrofollicular (A) and hyperplastic
lesions (B) in at least ten independent sectional planes per PBF-Tg or WT thyroid; N = 6-12
per genotype. Statistics analysed using Fisher’s exact test. C-E, Representative H&E stained
images of a macrofollicular lesion (C) and nodular hyperplasia (D) in PBF-Tg thyroids, and
of a WT thyroid (E) in 52 week old mice. F-G, Representative H&E stained images of
hyperplasia in PBF-Tg thyroids in 78 week old mice. H, Arrows highlight enlarged nuclei in
the hyperplastic lesion. I, Composite image of an entire thyroid lobe from a 78 week old
PBF-Tg mouse with diffuse goitre (DG) and hyperplastic regions (HP). Scale bars: 100 μm.
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Figure 4.
Altered gene expression and iodide uptake in PBF-Tg thyroids. A, Serum TSH analyses in
6-week old PBF-Tg and WT mice; N = 6. Relative mRNA expression of indicated growth
factor and TSHR in either PBF-Tg thyroids (B) or primary thyrocyte cultures (C) compared
to WT; N = 6-15. D, Detection of TSHR isoforms α and β by Western blot analyses in PBF-
Tg and WT thyroids; N = 4. E, Relative mRNA expression of PTTG, TG, TTF1, PAX8 and
NIS in PBF-Tg thyroids compared to WT; N = 6-13. F, Detection of NIS by
immunohistochemistry of PBF-Tg and WT thyroids. Scale bars: 100 μm. G, Relative 125I
uptake in primary thyrocyte cultures from PBF-Tg and WT mice; N = 5-6. Detection of
PBF-HA expression by Western blot analyses (H) and relative 125I uptake (I) in primary
PBF-Tg thyrocyte cultures either non-transfected (UT) or transfected with PBF and
scrambled (Scr) siRNA as indicated; N = 8-20. Data presented as mean ± SE
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Figure 5.
Cellular proliferation in PBF-Tg thyroids. A, Detection of pAkt and total Akt expression by
Western blot analysis of PBF-Tg and WT thyroids. B, Detection of pAkt, total Akt and PBF
by Western blot analysis of human thyrocytes transfected with either vector only (VO) or
pcDNA3-PBF (PBF). C, Quantification of cyclin D1 immunostaining in sex- and age-
matched PBF-Tg and WT thyroids, expressed as frequency of cyclin D1 positive cells per
1000 cells examined; N = 5062-12998 per thyroid. A total of 62,945 thyroid cells were
examined for cyclin D1 expression in 17 PBF-Tg and 13 WT thyroids. Data presented as
mean ± SE. Representative images of cyclin D1 staining in diffuse goitre regions (D) and
hyperplastic lesions (E) of PBF-Tg and WT thyroids are shown. Scale bars: 100 μm.
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Figure 6.
Functional interaction between PBF and NIS in human thyrocytes. A, Quantification of PBF
mRNA expression in MNG (N = 24) relative to normal thyroid (N = 11). Data presented as a
scatterplot. B, Detection of PBF and TSHR expression by Western blot analyses in MNG
and normal thyroids. C, Quantification of NIS mRNA expression in MNG (N = 24) relative
to normal thyroid (N = 11). Data presented as a scatterplot. D, Correlation of PBF and NIS
mRNA expression (shown as ΔCT values) in MNG and normal thyroid. Statistics analysed
using Spearman rank correlation. E-G, Detection of PBF expression by Western blot
analyses (E), quantification of NIS mRNA expression (F) and relative 125I uptake (G) in
primary human thyrocyte cultures transfected with either PBF or Scr siRNA as indicated; N
= 9-11. Data presented as mean ± SE.
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